Sareum Holdings (LSE:SAR) Growth Rank : 0 (As of Jun. 19, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Growth Rank?

Sareum Holdings has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sareum Holdings Growth Rank Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sareum Holdings (LSE:SAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

RYH0:Germany

Address

Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX

Website

http://www.sareum.com

Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.